Ranbaxy Seller To Pump Funds Into India’s Fortis, Religare
This article was originally published in PharmAsia News
Executive Summary
The seller of Ranbaxy Laboratories plans to use some of the proceeds from Japan's Daiichi Sankyo to make India's Religare and Fortis health care companies industry leaders in India. Ranbaxy CEO Malvinder Singh said that for the next several years, Ranbaxy would focus on becoming the No. 1 health care company in the country. In the long run, he said, the plan is to phase in Fortis as an international company. He rejected speculation Fortis would be combined with the Anil Ambani group. (Click here for more